Home > Gastroenterology > ECCO 2022 > Novel Treatment Modalities > Guselkumab shows encouraging safety and efficacy in ulcerative colitis

Guselkumab shows encouraging safety and efficacy in ulcerative colitis

Presented By
Prof. Axel Dignass, Agaplesion Markus Hospital, Germany

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ECCO 2022
Trial
Phase 2, QUASAR Induction
Guselkumab induction therapy was superior to placebo across key endpoints in patients with moderately to severely active ulcerative colitis (UC) in the phase 2b QUASAR trial. Moreover, the results showed a favourable safety profile of guselkumab in the study population. Guselkumab is an IL-23 inhibitor, approved for the treatment of psoriatic arthritis and psoriasis, and currently under investigation as a therapy for patients with inflammatory bowel disease (IBD), explained Prof. Axel Dignass (Agaplesion Markus Hospital, Germany) [1]. The double-blind, placebo-controlled, phase 2b QUASAR Induction Study 1 (NCT04033445) randomised 313 patients with moderately to severely active UC, who failed on conventional or advanced therapies, 1:1:1 to intravenous 400 mg guselkumab, 200 mg guselkumab, or placebo every 4 weeks. The primary endpoints were clinical responsea


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on